Cardiac and hepatic function are closely interconnected, with deterioration in one organ often accelerating disease progression in the other. Emerging evidence, including data suggesting semaglutide may slow or halt liver fibrosis progression, highlights the need to rethink how we manage patients with overlapping heart and liver disease. By examining the heart–liver axis, clinicians can gain insight into more integrated approaches to care and consider why this clinically important connection has only recently gained broader attention.

In this interview, Richard A. Chazal MD, MACC and Vishal N. Rao, MD, MPH examine the interconnectedness of cardiovascular (CV) and hepatic risk.